198 related articles for article (PubMed ID: 32268334)
1. Effect of Interleukin-2 Receptor Antibody Induction Therapy on Survival in Renal Transplant Patients Receiving Tacrolimus.
Ali H; Sharma A; Halawa A
Am J Nephrol; 2020; 51(5):366-372. PubMed ID: 32268334
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients.
Lim WH; Chadban SJ; Campbell S; Dent H; Russ GR; McDonald SP
Nephrology (Carlton); 2010 Apr; 15(3):368-76. PubMed ID: 20470309
[TBL] [Abstract][Full Text] [Related]
3. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
[TBL] [Abstract][Full Text] [Related]
4. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
[TBL] [Abstract][Full Text] [Related]
5. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
6. The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival.
Jouve T; Fonrose X; Noble J; Janbon B; Fiard G; Malvezzi P; Stanke-Labesque F; Rostaing L
Transplantation; 2020 Jun; 104(6):1263-1271. PubMed ID: 31415035
[TBL] [Abstract][Full Text] [Related]
7. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
[TBL] [Abstract][Full Text] [Related]
9. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
[TBL] [Abstract][Full Text] [Related]
10. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
[TBL] [Abstract][Full Text] [Related]
11. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting eGFR 5-year post-deceased donor renal transplant: analysis and predictive model.
Elbadri A; Traynor C; Veitch JT; O'Kelly P; Magee C; Denton M; O'Sheaghdha C; Conlon PJ
Ren Fail; 2015 Apr; 37(3):417-23. PubMed ID: 25585951
[TBL] [Abstract][Full Text] [Related]
13. Antithymocyte Globulin Versus Interleukin-2 Receptor Antagonist in Kidney Transplant Recipients With Hepatitis C Virus.
Bae S; Durand CM; Garonzik-Wang JM; Chow EKH; Kucirka LM; McAdams-DeMarco MA; Massie AB; Al Ammary F; Coresh J; Segev DL
Transplantation; 2020 Jun; 104(6):1294-1303. PubMed ID: 32433232
[TBL] [Abstract][Full Text] [Related]
14. Low-target tacrolimus in de novo standard risk renal transplant recipients: A single-centre experience.
Størset E; Åsberg A; Hartmann A; Reisaeter AV; Holdaas H; Skauby M; Bergan S; Midtvedt K
Nephrology (Carlton); 2016 Oct; 21(10):821-7. PubMed ID: 26854648
[TBL] [Abstract][Full Text] [Related]
15. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
[TBL] [Abstract][Full Text] [Related]
17. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.
Tan J; Wu W; Xu X; Liao L; Zheng F; Messinger S; Sun X; Chen J; Yang S; Cai J; Gao X; Pileggi A; Ricordi C
JAMA; 2012 Mar; 307(11):1169-77. PubMed ID: 22436957
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Interleukin-2 Receptor Antagonist Induction Therapy in Standard-Risk Renal Transplant Recipients Maintained on Tacrolimus: A Systematic Review and Meta-Analysis.
Ali H; Mohamed MM; Sharma A; Fulop T; Halawa A
Am J Nephrol; 2021; 52(4):279-291. PubMed ID: 33887727
[TBL] [Abstract][Full Text] [Related]
19. Rabbit anti-thymocyte globulin (rATG) versus IL-2 receptor antagonist induction therapies in tacrolimus-based immunosuppression era: a meta-analysis.
Ali H; Soliman KM; Shaheen I; Kim JJ; Kossi ME; Sharma A; Pararajasingam R; Halawa A
Int Urol Nephrol; 2020 Apr; 52(4):791-802. PubMed ID: 32170593
[TBL] [Abstract][Full Text] [Related]
20. Superior Patient and Graft Survival in Adult Liver Transplant with Rabbit Antithymocyte Globulin Induction: Experience with 595 Patients.
Montenovo MI; Jalikis FG; Li M; Yeh M; Dick A; Hansen R; Reyes JD
Exp Clin Transplant; 2017 Aug; 15(4):425-431. PubMed ID: 27309029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
